PMID- 32129940
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Aug
TI  - The efficacy of axitinib as a first-line treatment for metastatic renal cell 
      carcinoma.
PG  - 241-246
LID - 10.1111/ajco.13323 [doi]
AB  - AIM: To evaluate predictive factors which associated with oncological outcomes to 
      first-line axitinib for metastatic renal cell carcinoma (mRCC). METHODS: A 
      retrospective chart review was conducted patients who had been treated with 
      axitinib as first-line therapy for the treatment of mRCC from September 2013 to 
      February 2018. Axitinib was given by single daily oral administration at a dose 
      of 10 mg, which was reduced according to adverse events (AEs). We investigated 
      progression-free survival (PFS), overall survival (OS), objective response rate 
      (ORR) and AEs. RESULTS: Thirty-eight mRCC patients were enrolled. The median 
      follow-up duration of axitinib treatment was 11.3 months (range = 1.0-56.9). ORR 
      was 28.9%. Median PFS and OS was 12.8, and 17.9 months, respectively. In 
      univariate analysis, baseline lactate dehydrogenase (LDH), neutrophil, corrected 
      calcium (Ca), platelets (Plt) and time from diagnosis were selected as potential 
      predictive factors. Multivariate Cox's proportional hazards model analysis showed 
      that the number of risk factors were associated with PFS (P = 0.03) and OS 
      (P = 0.02). CONCLUSION: Baseline LDH, neutrophil, Ca, Plt and time from diagnosis 
      are predictive factors for both PFS and OS in first-line treatment with axitinib 
      for metastatic renal cell carcinoma.
CI  - (c) 2020 John Wiley & Sons Australia, Ltd.
FAU - Kameda, Tomohiro
AU  - Kameda T
AUID- ORCID: 0000-0003-4521-008X
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Takayama, Tatsuya
AU  - Takayama T
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Sugihara, Toru
AU  - Sugihara T
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Takeshima, Saki
AU  - Takeshima S
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Yamazaki, Masahiro
AU  - Yamazaki M
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Komatsubara, Maiko
AU  - Komatsubara M
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Kamei, Jun
AU  - Kamei J
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Fujisaki, Akira
AU  - Fujisaki A
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Ando, Satoshi
AU  - Ando S
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Kurokawa, Shinsuke
AU  - Kurokawa S
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
FAU - Fujimura, Tetsuya
AU  - Fujimura T
AD  - Department of Urology, Jichi Medical University, Tochigi, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200304
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Antineoplastic Agents)
RN  - C9LVQ0YUXG (Axitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Axitinib/pharmacology/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - axitinib
OT  - first-line
OT  - renal cell carcinoma
OT  - vascular endothelial growth factor
EDAT- 2020/03/05 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/03/05 06:00
PHST- 2019/07/27 00:00 [received]
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/03/05 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/03/05 06:00 [entrez]
AID - 10.1111/ajco.13323 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2020 Aug;16(4):241-246. doi: 10.1111/ajco.13323. Epub 2020 
      Mar 4.